Protein De Novo Sequencing from MtoZ Biolabs

publication date: Aug 21, 2019
author/source: MtoZ Biolabs

Protein molecules play a key role in kit development, diagnostic reagent development, and drug discovery. The primary structure of the protein molecule itself is the core of its biological function. Therefore, the accurate and rapid analysis of the complete sequence of the protein contributes to the functional study of the unknown protein, and is significant to the development and production of protein drugs including monoclonal antibodies.

Overview-on-Protein-De-Novo-SequencingTraditional protein sequence analysis technology, whether based on MALDI-TOF mass spectrometer or nano LC-MS/MS platform, requires the use of a sequence database containing the identified proteins in the protein identification process, and then the molecular weight data measured by mass spectrometry can be compared to the molecular weight data obtained after fragmentation of the database theoretical sequence, so as to achieve sequencing and identification of the protein.

There are many proteins in the actual protein sequence analysis that are not included in existing databases, such as a new protein that has not been reported, or a protein Based on the above requirements for unknown protein sequence and mutation analysis, MtoZ Biolabs’ high-resolution mass spectrometer Obitrap Fusion Lumos combines rich bioinformatics analysis experience to establish a new generation of protein de novo sequencing and mutation analysis platform, enabling fast and accurate analysis of protein primary structures.

that were purified from a new species. In many cases, we can get theoretical data, but the missing part is the key. The commercially modified enzymes in the market, for instance. The sequence modification information of the enzyme is a technical barrier for competitors who intend to reverse engineer, because sequence changes are diverse (point mutations, deletions, insertions, substitutions, modifications, fusions, etc.). There are thousands of possibilities, and usually no directional cues can be found. Not only an enzyme in reagents box, many protein drugs also need to be optimized by mutation to increase yield or stability. In many cases, the protein sequence produces some mutations, which may cause changes in biological activity and produce an immune response even if there are few sequence mutations in a drug, and this in turn causes huge commercial losses. 


Protein De Novo Sequencing and Mutation Analysis Process


Platform Advantages 


more news from MtoZ Biolabs


If you have not logged into the website then please enter your details below.



Popular this Month...

Our Top 10 most popular articles this month


Today's Picks...




Looking for a Supplier?

Search by company or by product


Company Name:




Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd


Previous | Next